NEW YORK, 06 mai 2024 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – NASDAQ:CLLS) a annoncé aujourd’hui, que, à la suite de de l’approbation du ministère français de l’économie et de la satisfaction des autres conditions suspensives, AstraZeneca (LSE/STO/Nasdaq : AZN) a réalisé l’investissement additionnel de 140 millions de dollars dans la Société tel que précédemment annoncé par Cellectis le 1er et le 15 novembre 2023 (l’ « Investissement Additionnel »).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.